4Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention [ J ]. Am Heart J, 2006,151 (2) :273-281.
5Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin [ J ]. Am J Cardiol, 2005,96(5 ) :34-38.
8Cannon CP,Giuqliano RP,Blazing MA,et al. Rationale and design of IMPROVE-IT( IMProved Reduction of Outcomes : Vytorin Effica- cy International Trial ) : comparison of ezetimbe/simvastain versussimvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes [ J 1. Am Heart J, 2008,156 ( 5 ) : 826-832.
9Califf RM, Harrington RA, Blazing MA,et al. Premature release of data from clinical trials of ezetimibe[ J]. N Engl J Med,2009,361 (7) :712-717.
10Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, et al. Ezetimibe reduces plaque inflammation in a rabbit model of athero- sclerosis and inhibits monocyte migration in addition to its lipid- lowering effect [ J ]. Br J Pharmacol, 2009,156 ( 8 ) : 1218 -1227.
6Davidson MH, Maki KC Pearson TA,et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E Technology (NEPTUNE) Ⅱ survey and implications for treatment under the recent NCEP Writing Group recommendations[J]. Am J Cardiol, 2005, 96(4): 556-563.
7Stein E, Stender S, Mata P,et al and Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypereholesterolemia:efficacy and safety of ezetimibe co-administered with atorvastatin[J].Am Heart J, 2004, 148(3):447-455.
8Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone and in combination with ezetiraibe in patients at high risk of cardiovascular disease (results from the EXPLORER Study)[J]. Am J Cardiol, 2007, 99(5): 673-680.
9Baigent C, Keech A Kearney PM,et al. and Cholesterol Treatment Trialists'(CTT) Collaborators. Efficacy and safety of cho lesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J].Lancet, 2005, 366 (9493):1267-1278.
10Almagor M, Keen A, Banai S. Increased c - reactive Protein level after coronary stent implantation in patients with stable coronary artery disease [ J ]. Am Heart J,2003,145:248 - 253.
5Soares R, Costa C. Oxidative stress, inflammation and angiogenesis in the metabolic syndrome [ M ]. Germany : Springer verlag, 2009 : 163.
6Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes [ J]. Diabetologia,2008,51 (10) :1930-1932.
7Gonzalez AS, Guerrero DB, Soto MB, et al. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin [J]. Eur J Clin Nutr,2006,60(6) :802-809.
8Rodilla E,Costa JA, Mares S, et al. Impact of metabolic syndrome on CRP levels [ J ]. Rev Clin Esp ,2006,206 (8) :363-368.
9Iwasaki T, Nakajima A, Yoneda M, et al. Relationship between the serum concentrations of C-reaetive protein and parameters of adiposity and insulin resistance in patients with type 2 diabetes mellitus [ J]. Endocr J,2006,53 (3) :345-356.
10Fornengo P, Bosio A, Epifani G, et al. Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors [ J]. Diabet Med, 2006,23 (7) :775-779.
